Clascoterone and LGD-4033 Interaction

Monitor
Mechanism-based 51% confidence

Clascoterone and LGD-4033 have an interaction requiring monitoring for interaction with 51% confidence. Both Clascoterone and LGD-4033 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. These compounds primarily affect different organ systems.

Compound Profiles

Clascoterone

Topical Androgen Receptor Inhibitor | Acne & Hair Loss

Clascoterone acts as a competitive antagonist of the androgen receptor (AR). When applied topically, it penetrates the skin and binds directly to androgen receptors in target tissues -- sebaceous glands (for acne) and dermal papilla cells of hair follicles (for alopecia).

Half-life: Short topical (local action; rapidly metabolized to cortexolone) Typical dose: Acne: 1% cream 2x/day | Hair loss: 7.5% solution once daily hair loss, skin
androgen receptorngf androgenicteratogenic
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Skin
low

Shared Safety Flags

2x 2 androgenic compounds (Clascoterone, LGD-4033). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the teratogenic safety flag (Clascoterone, LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take Clascoterone with LGD-4033?

Yes, but with caution. Both Clascoterone and LGD-4033 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. Regular monitoring is advised.

Is Clascoterone and LGD-4033 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, teratogenic. Monitor accordingly.

What are the interactions between Clascoterone and LGD-4033?

Both Clascoterone and LGD-4033 carry androgenic activity. Additive androgenic load increases risk of acne, hair loss, and prostate effects. Monitor for dose-dependent side effects. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time Clascoterone and LGD-4033?

Clascoterone has a half-life of Short topical (local action; rapidly metabolized to cortexolone) and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Clascoterone vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.